HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.

ABSTRACT: BACKGROUND:Therapies targeting anti-tumor T-cell responses have proven successful in the treatment of a variety of malignancies. However, as most patients still fail to respond, approaches to augment immunotherapeutic efficacy are needed. Here, we investigated the ability of histone deacetylase 6 (HDAC6)-selective inhibitors to decrease immunosuppression and enhance immune function of melanoma patient T-cells in ex vivo cultures. METHODS:T-cells were harvested from peripheral blood or tumor biopsies of metastatic melanoma patients and cultured in the presence of pan-, class-specific or class-selective histone deacetylase (HDAC) inhibitors. Changes in cytokine production were evaluated by Luminex and intracellular flow cytometry staining. Expression of surface markers, transcription factors

SUBMITTER: Laino AS 

PROVIDER: S-EPMC6366050 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature